Colorectal Cancer

 
Pharmacy-Based FIT Distribution May Expand CRC Screening: Daily Dose
September 09, 2025

Your daily dose of the clinical news you may have missed.

Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks
August 28, 2025

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Mailed FIT Kits Boost CRC Screening at Ages 45–49: Daily Dose
August 21, 2025

Your daily dose of the clinical news you may have missed.

Pharmacy-Based FIT Distribution Could Broaden CRC Screening, But Results Must be Delivered with Care, New Survey Reveals
August 18, 2025

If FIT results indicated colonoscopy, respondents preferred personal follow-up vs digital; significant barriers to undergoing fear of the test and positive cancer finding were the most significant barriers to follow-up.

More US Adults in Their 40s Undergoing CRC Screening After Age Threshold Lowered: Daily Dose
August 18, 2025

Your daily dose of the clinical news you may have missed.

One-Third of US Adults Aged 45-49 Were Up-to-Date on Colorectal Cancer Screening in 2023
August 05, 2025

New data show up-to-date CRC screening rose from 20.8% in 2019 to 33.7% in 2023, with gains driven by stool testing and colonoscopy.

FIT Tests, Direct Mailed, Increase Initiation of CRC Screening in Adults Aged 45 to 49
August 05, 2025

For initiating colorectal cancer screening in average-risk young adults, a default mailed outreach strategy outperformed 3 active choice options in a randomized study.

Early Colorectal Cancer Screening at Ages 40-49 Reduces Long-Term Incidence and Mortality
June 18, 2025

As the incidence of young-onset colorectal cancer continues to rise, the findings from a large Taiwanese population-based study support lowering the age for initial screening.

GLP-1s May Cut Obesity-Related Cancer Risk: Daily Dose
June 13, 2025

Your daily dose of the clinical news you may have missed.

Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
June 04, 2025

Breakthrough device designation for the multicancer detection test is supported by clinical validation data demonstrating an overall specificity of 98.6% and sensitivity of 60%.